Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - October 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of October 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2011-01560 Information regarding ZENHALE by Merck Canada Inc. Disclosed in part 1,169
A-2012-00054 Information regarding BREVICON, Drug Identification Number (DIN) 02187086, 02187094, 02189054 and 02189062. Disclosed in part 1,208
A-2012-00565 Documents regarding the compound strontium ranelate. Disclosed in part 304
A-2012-00992 Information regarding PRE-PEN, Drug Identification Number (DIN) 00328693 by ALK-ABELLO INC. Disclosed in part 48
A-2012-01482 Adverse Reaction Report (AER) for Celexa. Report numbers: 000448898, 000461968. Disclosed in part 3
A-2012-01537 Adverse Reaction Report (AER). Report numbers: 000448526, 000462409, 000450096, 000412611. Disclosed in part 8
A-2012-01633 Adverse Reaction Report (AER) for Zyprexa. Report numbers: 000459965, 000461510, 000466655, 000466878, 000468467. Disclosed in part 13
A-2013-00604 Documents regarding existing or possible future impacts on Canadians' health from radiation originating from damaged nuclear reactors at Fukushima-Daiichi, Japan. (Jul 15, 2013 to Sep 30, 2013). Disclosed in part 359
A-2013-00758 All correspondence regarding varenicline (Champix or Chantix) with foreign regulators. (Jan 1, 2001 to Oct 17, 2013). Disclosed in part 20
A-2013-00798 Documents pertaining to discussions on sugar and sweeteners from Health Canada Food Expert Advisory Council Meetings. (Oct 10, 2008 to Oct 9, 2013). No records exist 0
A-2013-01556 Documents regarding assessments of animal laboratory and experimental research available in the peer reviewed literature which is associated with low frequency noise and infrasound exposure. (Jan 1, 2000 to Mar 31, 2014). All disclosed 16
A-2014-00185 Information regarding REGUBIL, Drug Identification Number (DIN) 00557110 by LABORATOIRE RIVA INC. Disclosed in part 3
A-2014-00212 All studies and/or expert opinions relating to diacetylmorphine (also known as prescription heroin) in relation to the Ministry's decision to revise the Special Access Program to forbid the prescription of diacetylmorphine (as announced by the Minister on October 2, 2013). (Jun 1 2013 to Oct 31, 2013) Disclosed in part 45
A-2014-00344 Documents regarding the Jordan's Principle stories aired on Aboriginal Peoples Television Network National News on May 26, 27 and 28, 2014. Disclosed in part 86
A-2014-00345 Information regarding the pest control product Extenda Shield by Fusion Animal Health Inc. Disclosed in part 496
A-2014-00355 Document regarding the following contracts:
4500312571, 4500309976, 4500310388, 4500311833, 4500310991.
Disclosed in part 278
A-2014-00368 All correspondence and briefing notes relating to the demolition of J.R. Nakogee School in Attawapiskat. (Feb 1, 2009 to May 31, 2009). Disclosed in part 297
A-2014-00372 Data describing holders of a Personal Use Production Licence. (Mar 1, 2009 to Mar 1, 2014). Disclosed in part 1,377
A-2014-00388 Adverse Reaction Report (AER) for Micardis/Aggrenox. Report number: 000214300. Disclosed in part 10
A-2014-00397 Documents identifying the source of the organization funding the wind turbine community noise and health study. Disclosed in part 59
A-2014-00406 All complaints regarding any homeopathic medicine made by Homeocan, marketed to or used by children. (Jan 1, 2007 to Jul 2, 2014). No records exist 0
A-2014-00407 All complaints regarding any homeopathic medicine made by Boiron, marketed to or used by children. (Jan 1, 2007 to Jul 2, 2014). No records exist 0
A-2014-00415 Adverse Reaction Report (AER) for Micardis/Aggrenox. Report number: 000310987. Disclosed in part 4
A-2014-00427 Adverse Reaction Report (AER). Report number: 000544295. Disclosed in part 10
A-2014-00429 Adverse Reaction Report (AER). Report number: E2B_00031101. Disclosed in part 16
A-2014-00437 Documents previously released regarding "marihuana". (Jan 1, 2010 to May 28, 2014). Disclosed in part 3,029
A-2014-00444 Documents regarding radon and real estate transactions. (Jan 1, 2006 to 14 Mar 2014). Disclosed in part 499
A-2014-00461 Documents regarding the original application, efficacy data and toxicology studies for the pesticide CT-511 Presurrized, Pest Control Product Number 22319. All disclosed 18
A-2014-00471 Documents regarding the completed appointment process for 12-AHS-NCR-EA-083. Disclosed in part 158
A-2014-00505 Adverse Reaction Report (AER). Report numbers: 000599489, 000583844. Disclosed in part 5
A-2014-00506 Documents regarding wind turbine noise and health study and the conduct of noise monitoring at an individual's home. Disclosed in part 61
A-2014-00510 Adverse Reaction Report (AER) for the following products/report numbers: Cipralex (000581482, 000582572, 000582637, 000583705, 000583733, 000584039, 000586423, 000588443, 000590162, 000590163, 000591124, 000598351), Treanda (000581479, 000587870) Disclosed in part 27
A-2014-00524 Results of sampling of fish done on October 30, 2013 during visit to inspection of aquaculture site #1359 (Blue Island) in Jordan Bay, Nova Scotia. Results of sample #AT-2013-JB-0009. Disclosed in part 1
A-2014-00535 Adverse Reaction Report (AER) for Synthroid. Report numbers: 000590021, 000596957. Disclosed in part 11
A-2014-00572 Study carried out jointly by Health Canada and the National Research Council on Mitigation Strategies to prevent the infiltration of pollutants from attached garages into the living spaces of residential homes. All disclosed 46
A-2014-00588 Adverse Reaction Report (AER) for NORVIR. Report number: 000577997. Disclosed in part 2
A-2014-00591 Adverse Reaction Report (AER) for HUMIRA. Report numbers: 000562447, 000567628, 000578568. Disclosed in part 10
A-2014-00592 Adverse Reaction Report (AER) for HUMIRA. Report numbers: 000577168, 000567554, 000565280. Disclosed in part 5
A-2014-00607 Documents regarding the volume and dollar value of Natural Health Products coming into Canada from other countries for personal use which do not have a Natural Product Number (NPN). (Jan 1, 2011 to Dec 31, 2013). All disclosed 19
A-2014-00633 Documents pertaining to frauds and thefts, including collusion in contracts or involving Health Canada. (Jan 1, 2012 to Aug 25, 2014). Disclosed in part 170
A-2014-00640 Budget and expenditures data. (Jan 1, 2005 to Aug 21, 2014). All disclosed 815
A-2014-00657 All appointments term and casual employees in the National Capital Region under the term of the Public Service Employment Act (Apr 1, 2014 to Aug 31, 0214). All disclosed 11
A-2014-00659 Various contracts processed in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Task and Solutions Professional Services (TSPS) and for Task-Based Informatics Professional Services (TBIPS). (Apr 1, 2014 to Jul 31, 2014). Disclosed in part 20
A-2014-00660 Call-ups under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services. (Apr 1, 2014 to Jul 31, 2014). Disclosed in part 302
A-2014-00664 A listing of the Access to Information requests submitted to Health Canada. (Jul 1, 2014 to Jul 31, 2014). Disclosed in part 13
A-2014-00665 A listing of the Access to Information requests submitted to Health Canada. (Aug 1, 2014 to Aug 31, 2014). Disclosed in part 7
A-2014-00676 Rating guide that was used in Selection Process Number 13-SHC-FNIHB-ACIN-01. All disclosed 9
A-2014-00682 Briefing lists that have been prepared for July and August 2014. Disclosed in part 17
A-2014-00691 All communications regarding C4ST’s (Canadians for Safe Technology) email of 16 July 2014 sent in response to public consultation of Safety Code 6. (Jul 16, 2014 to Sep 5, 2014). Disclosed in part 5
A-2014-00692 All communications regarding the 140 Omitted studies report (email of July 15, 2014) sent in response to the public consultation of Safety Code 6. (Jul 15, 2014 to Sep 5, 2014). No records exist 0
A-2014-00694 Adverse Reaction Report (AER). Report numbers: 000588330, 000588586, 000589770, 000589775, 000590099. Disclosed in part 13
A-2014-00713 Adverse Reaction Report (AER) for Neostrata HQ AHA Gel (hydroquinone). Report number: 000559894. Disclosed in part 1
A-2014-00715 Adverse Reaction Report (AER). Report number: 000536162. Disclosed in part 2
A-2014-00724 Information on a letter-writing campaign in 2007 to several members of the Ontario government, regarding the well-being and development of Aboriginal people living on reservations in Northern Ontario. No records exist 0
A-2014-00733 List of briefing notes prepared for the Minister. (Sep 1-29, 2014). Disclosed in part 8
A-2014-00745 Adverse Reaction Report (AER) for Lantus. Report number: 000583202. Disclosed in part 1
A-2014-00753 A listing of the Access to Information requests submitted to Health Canada. (Sep 1, 2014 to Sep 30, 2014). Disclosed in part 9
A-2014-00791 Adverse Reaction Report (AER). Report numbers: 000524035, 000527433. Disclosed in part 2
A-2014-00801 Adverse Reaction Report (AER) for Lantus. Report number: 000590500. Disclosed in part 2
A-2014-00811 Adverse Reaction Report (AER). Report number: 000569781. Disclosed in part 1
A-2014-00812 Adverse Reaction Report (AER). Report numbers: 000561541, 000490999, 000500863, 000501788, 000505482, 000522657. Disclosed in part 19